Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Yoga can improve cognitive functioning and reduce depression in dementia caregivers

For every individual who's a victim of Alzheimer's - some 5.4 million persons in the United States alone - there's a related victim: the caregiver. Spouse, son, daughter, other relative or friend, the loneliness, exhaustion, fear and most of all stress and depression takes a toll.

14 Mar 2012

Biomedical research advances through new Australian Institute

The Institute of Biomedical Engineering and Technology (BMET) will be officially opened this evening at the University of Sydney, and will significantly advance this highly multidisciplinary research for life sciences and medicine.

14 Mar 2012

JAK-STAT inhibitors reverse MS-like disease in mice

A new class of drugs completing clinical trials soon for rheumatoid arthritis should be examined as a treatment for multiple sclerosis, according to the authors of a University of Alabama at Birmingham study published today in the Proceedings of the National Academy of Sciences.

13 Mar 2012

Human diseases with Drosophila counterparts discussed at annual conference

More than two-thirds of human genes have counterparts in the well-studied fruit fly, Drosophila melanogaster, so although it may seem that humans don't have much in common with flies, the correspondence of our genetic instructions is astonishing. In fact, there are hundreds of inherited diseases in humans that have Drosophila counterparts.

12 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

Concerns about aging in good health

Do men harbour concerns about aging in good health? Do they confide these concerns to their physicians? Are men's concerns the same as women's? The answers to these questions can be found in a large cross-sectional survey of 2325 Canadian men, aged 55 to 97 years old, led by Dr. Cara Tannenbaum, Geriatrician and the Michel Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging at the Institut universitaire de gériatrie de Montréal (IUGM) which is affiliated with the Université de Montréal.

10 Mar 2012

Report: Alzheimer's care to cost $200 billion this year

The report issued by the Alzheimer's Association also estimates that as many as 800,000 Americans have this illness and live alone. As many as half of these people don't have specific arrangements to help them get care.

9 Mar 2012

Study uncovers critical process in understanding degeneration of brain cells sensitive to AD

A research group led by Dr. A. Claudio Cuello of McGill University's Faculty of Medicine, Dept. of Pharmacology and Therapeutics, has uncovered a critical process in understanding the degeneration of brain cells sensitive to Alzheimer's disease.

9 Mar 2012

Patients with advanced Alzheimer’s benefit from drugs: Study finds

According to new developments patients with advanced Alzheimer’s disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated.

8 Mar 2012

Surgical intervention can be life-restoring for people with intractable temporal lobe epilepsy

While the thought of any type of surgery can be disconcerting, the thought of brain surgery can be downright frightening. But for people with a particular form of epilepsy, surgical intervention can literally be life-restoring.

8 Mar 2012

Berry fruits help the brain stay healthy in several ways

Strong scientific evidence exists that eating blueberries, blackberries, strawberries and other berry fruits has beneficial effects on the brain and may help prevent age-related memory loss and other changes, scientists report.

8 Mar 2012

Some top researchers no longer think of glaucoma solely as an eye disease

A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.

8 Mar 2012

Women with multiple pregnancies may have reduced risk of MS

Women who have multiple pregnancies may have a lower risk of developing multiple sclerosis (MS), according to research published in the March 7, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

8 Mar 2012

March issue of NeuroPerspective reviews therapeutics for ADHD

NeuroPerspective, the independent, monthly review of the neurotherapeutics area, has released its March issue, which reviews the field of therapeutics for Attention Deficit Disorder.

8 Mar 2012

Researchers document unknown biological mechanism in the blood-brain barrier

Researchers at the University of Copenhagen have documented a previously unknown biological mechanism in the brain's most important line of defence: the blood-brain barrier. Scientists now know that the barrier helps maintain a delicate balance of glutamate, a vital signal compound in the brain.

8 Mar 2012

Researchers validate CatB protease as target for Alzheimer's

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.

8 Mar 2012

New research provides explanation for some of autism's mysteries

New research from Carnegie Mellon University's Marcel Just provides an explanation for some of autism's mysteries - from social and communication disorders to restricted interests - and gives scientists clear targets for developing intervention and treatment therapies.

7 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Persistent depression may increase risk of cognitive decline in older patients with CAD

Persistent depression symptoms may be associated with significantly greater declines in cognitive performance in older patients with coronary artery disease who underwent cardiac catheterization, according to a study published in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

6 Mar 2012

New AD marker can predict mental decline

A new marker of Alzheimer's disease can predict how rapidly a patient's memory and other mental abilities will decline after the disorder is diagnosed, researchers at Washington University School of Medicine in St. Louis have found.

6 Mar 2012